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ABSTRACT 
This systematic review evaluated the effectiveness of strategies to identify and manage 
patients with familial risk of breast, ovarian, colorectal and prostate cancer in primary 
care to improve clinical outcomes. MEDLINE, EMBASE, CINAHL and Cochrane 
library were searched from January 1980 to October 2017. We included randomised 
controlled trials (RCT) and non-randomised studies of interventions (NRSI). Primary 
outcomes were cancer incidence, cancer related clinical outcomes or identification of 
cancer predisposition; secondary outcomes were appropriateness of referral, uptake of 
preventive strategies, cognitive and psychological effect. From 11842 abstracts, 111 full 
texts were reviewed and three eligible studies (nine articles) identified. Two were 
cluster RCTs and one NRSI; all used risk assessment software. No studies identified our 
primary outcomes, with no consistent outcome across the three studies. In one RCT, 
intervention improved the proportion of genetic referrals meeting referral guidelines for 
breast cancer (OR 4.5, 95% CI 1.6 to 13.1). In the other RCT, there was no difference in 
screening adherence between the intervention and control group. However, there was 
borderline increased risk perception (OR 1.89, 95% CI 0.99 to 3.59) in the subgroup 
that under-estimated their colon cancer risk. In the NRSI, there was no change in 
psychological distress in patients at increased familial breast cancer risk, but population 
risk patients had reduced anxiety after intervention (state anxiety mean change –3, 95% 
CI -5 to -2). Future studies should have better defined comparator groups, longer follow 
up, and assess outcomes using validated tools. 
242 words 
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INTRODUCTION 
Familial cancer risk increases an individual’s life time chance of developing cancer and 
at an earlier age of onset (Kerber et al. 2005; Paluch-Shimon et al. 2016; Qureshi et al. 
2009). A Swedish Cancer Registry study found that cancers with the highest familial 
proportions (proportion of cases with affected parents/siblings) were prostate, breast and 
colorectal cancer (Hemminki et al. 2008). As well as being the most common cancers 
worldwide, they are associated with the commonest cancer related gene mutations 
(Qureshi et al. 2007; World Cancer Research Fund). For instance, BRCA1 mutations 
increase the risk of breast, ovarian and prostate cancer, whilst DNA mismatch repair 
gene mutations are associated with Lynch Syndrome (Qureshi et al. 2007). 
Familial cancers are usually divided into three categories. For example, the English 
National Institute for Health and Care Excellence (NICE) categorised breast cancer risk 
into: at or near population (<17% lifetime risk), moderate (17% to 29%) and high risk 
(>30%) (NICE 2017). A 2005 California population survey reported the prevalence of 
strong and moderate familial cancer risk to be 5% and 7% for breast, 1% and 5% for 
colorectal and prostate cancer. This risk stratification was based on the proximity of 
affected relatives and age at cancer diagnosis (Scheuner et al. 2010). 
As illustrated above, the definition of familial cancer risk varies in different countries 
and guidelines. Nevertheless, high risk generally indicates probability of single gene 
disorder with Mendelian inheritance (Duffy et al. 2013; Qureshi et al. 2007; Scheuner et 
al. 2010). Conversely, moderate risk may be due to combinations of multiple low 
penetrance gene mutations with or without shared environmental or behavioural risk 
factors (Qureshi et al. 2007). 
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Preventive measures such as surveillance, prophylactic surgery or chemoprevention can 
reduce cancer incidence and mortality for patients with familial cancer risk (Carbine et 
al. 2018; Cuzick et al. 2013; Domchek et al. 2010; Duffy et al. 2013). A Cochrane 
review found that bilateral risk reducing mastectomy decreased breast cancer incidence 
and death, particularly in women with BRCA 1/2 mutations (Carbine et al. 2018). The 
FH01 study estimated that annual mammogram for women aged 40-49 with moderate 
familial breast cancer risk (defined as at least 3% risk for this age group) reduced breast 
cancer mortality by 40% (Duffy et al. 2013).  In a 15-year controlled trial, colonoscopy 
screening at three-year intervals reduced the colorectal cancer rate by 62% and overall 
mortality by 65% in families with Lynch Syndrome (Järvinen et al. 2000). 
For at-risk patients to benefit from these preventive measures, primary care providers 
play a crucial role. To assess familial cancer risk, primary care providers need to collect 
a family history, the English NICE guideline suggests using family history tools to 
collect comprehensive family histories (NICE, 2017). Clinical decision support systems 
can then be used to translate this information into risk strata with evidence-based 
recommendation on appropriate management, e.g. referral to genetic services for those 
at high familial risk or reassurance of patients at near population risk (NICE, 2017; 
Paluch-Shimon et al. 2016; U.S. Preventive Services Task Force, 2015). 
However, it is still unclear if familial cancer risk assessment and management in 
primary care improves clinically relevant outcome, such as cancer morbidity and 
mortality. Previous systematic reviews focused on the impact of multifactorial cancer 
risk assessment tools, the validity of family history tools, specialist risk assessment 
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services and familial breast cancer only (Cleophat et al. 2018; Hilgart et al. 2012; 
Qureshi et al. 2009; Walker et al. 2015). 
The current systematic review focused on the effectiveness of primary care 
interventions to identify and manage patients at familial cancer risk, to improve clinical 
outcomes for breast, ovarian, prostate and colorectal cancers. This will help policy 
makers decide which familial cancer risk assessment interventions are worth adopting 
and help researchers identify the gaps in evidence. 
METHODS 
The Cochrane Collaboration’s guidance on review of interventions and the PRISMA-P 
checklist were followed (Higgins et al. 2011b; Shamseer et al. 2015). The protocol was 
registered on PROSPERO in December 2017 (PROSPERO 2017).   
Literature search 
Databases searched were: MEDLINE, EMBASE, CINAHL, and Cochrane library. 
Aligned with the introduction of familial cancer clinics in the late 1980s, the search 
period was from 1st Jan 1980 to 4th October 2017 (Hilgart et al. 2012). We used 
controlled vocabulary and free text terms based on the concepts of ‘cancer: breast, 
ovarian, colorectal and prostate’, ‘familial/hereditary cancer’, and ‘primary health care’.  
With the Zetoc database, we also searched the table of contents within the last five years 
for: Journal of Community Genetics, European Journal of Human Genetics, Genetics in 
Medicine, and Public Health Genomics. Other searches included clinical trial registries 
(U.S. National Institutes of Health (www.clinicaltrials.gov), ISRCTN registry, WHO 
International Clinical Trials Registry Platform), The Networked Digital Library of 
Theses and Dissertations, the conference proceedings within the last five years for 
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European Society of Human Genetics Conference and American College of Medical 
Genetics and Genomics annual meetings, and the reference list of included studies. See 
supplementary material 1 for full details of the search strategy. 
Study selection 
Two authors screened the titles and abstracts (SL and MP/BD) and full texts (SL and 
MP) independently. Discrepancies were resolved with a third author (NQ). Authors of 
studies were contacted where clarification were required.  
Studies were eligible if published in English and evaluated an intervention that 
identified and managed patients at risk of familial breast, ovarian, colorectal or prostate 
cancer. Data must have been presented separately for each cancer type, except breast 
and ovarian cancer, as BRCA1/2 associated breast and ovarian cancer is a recognised 
hereditary cancer syndrome (Petrucelli et al. 2010). Randomised controlled trials (RCT) 
and non-randomised studies for intervention (NRSI) were eligible. Reviews, genetic 
epidemiology studies with no clinical intervention, stand-alone guidelines, case reports, 
editorials, qualitative studies, abstracts and studies with no comparator arm were 
excluded.  
Participants included were adults aged >18 with no previous history of cancer or known 
cancer genetic mutation. The intervention must have been based in primary care or non-
specialist community health service and care managed by primary care providers. We 
defined primary care providers as health professionals who delivered care to 
undifferentiated patients as the first contact point in the community. This could be a 
general practitioner (family doctor or family physician), internal medicine physician, or 
obstetrician/ gynaecologist practising in the community (Qureshi et al. 2007). 
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The primary outcomes were cancer incidence; cancer related morbidity, mortality and 
survival; and identification of cancer predisposition (increased familial risk) as defined 
by study authors. Secondary outcomes were appropriateness of specialist referrals (as 
defined by study authors); uptake of preventive strategies; cognitive and psychological 
effect measured with validated tools. 
Data extraction and analysis 
Data on study characteristics and pre-specified outcomes were extracted by two 
reviewers independently (SL and BD/JL) using standardised forms and discrepancies 
resolved with a third author (NQ). Where there were multiple publications from the 
same study, the data were grouped together and treated as a single study (Higgins et al. 
2011b). 
Quality assessment 
Two authors reviewed the risk of bias for the included studies independently (SL and 
NQ/SW) with discrepancies resolved with a third author (SW/NQ). The Cochrane 
Collaboration Risk of Bias tool was used for RCT, and the ROBINS-I tool was used for 
NRSI (Higgins et al. 2011a; Sterne et al. 2016). The GRADE approach was used to rate 
the certainty of evidence for the included outcomes (Schünemann et al. 2013). 
RESULTS 
From the initial 11842 titles and abstracts, we screened 111 full texts for eligibility 
(figure 1). Three studies comprising nine articles were included (Emery et al. 2007; 
Family Healthware Trial (O’Neil et al. 2009; Acheson et al. 2010; Rubinstein et al. 
2011a; Rubinstein et al. 2011b; Ruffin et al. 2011; Wang et al. 2012; Wang et al. 2015); 
Van Erkelens et al. 2017). Only four outcomes were identified. No studies reported the 
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same outcomes. Three further studies were identified that are ongoing or awaiting 
publication (ISRCTN 2014; Naicker et al. 2013; Voils 2017). Supplementary material 2 
presents the table of excluded studies with reasons for exclusion. 
Due to the limited number of included studies with varying study designs and study 
interventions, meta-analysis was not feasible. The outcomes were presented as a 
narrative summary. See supplementary material 3 for further details. 
Included studies 
Table 1 summarised the characteristics of the three included studies. Of these, two were 
cluster RCTs (Emery et al. 2007; Family Healthware Trial) and one NRSI (uncontrolled 
before and after study) (Van Erkelens et al. 2017). Two studies were based in Europe 
and one in the USA. Two studies evaluated interventions for breast, ovarian and 
colorectal cancer, and one study for breast cancer only. Follow up duration ranged from 
2 weeks to 12 months, with a median follow up time of 6 months. The average age of 
patients ranged from 51 to 56. Patients were predominantly white, female, and college 
educated. 
All three studies used a bespoke software for familial cancer risk assessment: a clinician 
pedigree drawing tool based on patient completed family history questionnaire (Emery 
et al. 2007), a patient facing familial risk assessment tool online or via telephone 
interview (Family Healthware Trial), and a patient online self-test (Van Erkelens et al. 
2017). All three subsequently generated a risk based action plan: one informed general 
practitioners who needed genetic referral (Emery et al. 2007), another provided 
personalised familial risk assessment outcome and prevention plan for patients and all 
types of primary care providers (Family Healthware Trial), and the final study advised 
9 
 
patients with increased risk to consult their primary care providers (unspecified health 
care professionals) (Van Erkelens et al. 2017). 
Two studies used a proactive approach by screening all patients with an upcoming 
appointment with their primary care provider (Family Healthware Trial) or attending 
population-based breast cancer screening (Van Erkelens et al. 2017). One study 
employed a reactive approach and only conducted a familial risk assessment when 
approached by patients concerned about their cancer family history (Emery et al. 2007). 
Primary outcome 
No studies identified the review’s primary outcome (cancer incidence, cancer related 
morbidity, mortality, survival, or identification of cancer predisposition). Although the 
Family Healthware Impact Trial reported the characteristics of patients with interim 
cancer diagnosis during the six month follow up period (five intervention and two 
control patients reported a new breast cancer diagnosis; 17 intervention and 10 control 
patients reported ‘other’ cancer; none reported colon or ovarian cancer diagnosis), the 
authors excluded these patients from the analyses of screening adherence as it was not 
clear whether the tests or consultations were performed for screening or diagnostic 
purposes during the intervention period (Rubinstein et al. 2011a). 
Secondary outcome 
None of the three studies reported the same outcomes. The four secondary outcomes 
reported were: appropriateness of specialist referrals, uptake of preventive strategies, 
patients’ self-reported risk perception and patients’ self-reported anxiety and depression. 
Details of each outcome were described below. Using the GRADE approach, these 
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outcomes had low to very low certainty of evidence (table 2). This is driven by 
weakness in the study design, leading to risk of bias (see risk of bias section).  
I. Appropriateness of specialist referrals 
Emery et al.’s cluster RCT showed that the use of a risk assessment and decision 
support software resulted in significantly higher proportion of general practitioners’ 
referral letters meeting the referral guidelines for breast cancer (93% intervention vs 
73% control, OR 4.5, 95% CI 1.6 to 13.1) but not for colorectal cancer (99% vs 92%, 
OR 6.5, 95% CI 0.5 to 83.7) (2007).  
After specialist review at the genetic clinic, the proportion of general practitioners’ 
referrals that were confirmed as increased risk was similar for intervention and control 
for breast cancer (77% vs 70%, OR 1.4, 95% CI 0.6 to 3.5). In contrast, for colorectal 
cancer, the proportion assessed to be at increased risk by the specialist was lower in the 
intervention arm (56% vs 85%, OR 0.2, 95% CI 0.1 to 0.8) (Emery et al. 2007). 
II. Uptake of preventive strategies 
The Family Healthware cluster RCT found that six months post-intervention, there was 
no significant difference in improved adherence between the intervention and control 
arm for risk-based mammography (improvement in adherence, 9% intervention vs 7% 
control, p=0.82) and colorectal cancer screening (8% vs 7%, p=0.95). This was also the 
case for the subgroup of patients who were not adherent at baseline. During the 
intervention period, there was no difference between study arm in the number of women 
receiving CA-125 blood test and transvaginal ultrasound for ovarian cancer risk 
(supplementary material 3) (Rubinstein et al. 2011a).  
III. Cognitive effect: Patients’ risk perception 
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The Family Healthware trial did not report this outcome for all patients. However, in the 
subgroup of patients who under-estimated their risk, more of the intervention patients’ 
risk perception became consistent with their risk status at six months for colorectal 
cancer, although this was of borderline significance (17% vs 10%, OR 1.89, 95% CI 
0.99 to 3.59). This was not observed for breast or ovarian cancer (Rubinstein et al. 
2011a).  
IV. Psychological effect: Patients’ anxiety & depression 
Van Erkelens et al.’s NRSI used the State-Trait Anxiety Inventory (STAI) and Hospital 
Anxiety and Depression Scale (HADS). The analysis of the total study population was 
not presented. Subgroup analysis by risk status was provided: women told to be at 
population risk for breast cancer had reduced anxiety immediately after self-risk 
assessment (mean change of state anxiety -2, 95% CI -2 to -1) and at two weeks (-3, 
95% CI -5 to -2). The HADS score remained unchanged at two weeks. For women at 
increased breast cancer risk, there was no consistent change in anxiety and depression 
(table 2). The mean score for STAI and HADS were below the levels of clinical 
significance and similar to those of the general population (supplementary material 3) 
(2017). 
Risk of bias 
All three included studies were at high risk of bias (table 3). For Emery et al.’s cluster 
RCT, allocation concealment, blinding of participants and clinicians were not possible. 
The patient’s non-attendance at the genetic clinic was 28% (45/162) for intervention and 
38% (32/84) for control, contributing to attrition bias. Responder bias was evident from 
the 74% (125/170) practices that declined to participate. The author commented that this 
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recruitment rate is consistent with similar primary care trials and that practices that were 
interested in genetic medicine were more likely to participate (2007). 
The Family Healthware trial had no description of the random sequence generation or 
allocation concealment. From the published study design, there appeared to be no 
blinding. The participant recruitment rate was low (18%) with high attrition: 20% 
intervention (542/2650) and 20% control (324/1598) participants withdrew from 
consent to follow up. Results for the change in risk perception was only reported for the 
subgroup who under-estimated their risk. Selection of participants who were free of 
comorbidities led to healthy volunteer bias. The lengthy baseline questionnaire may 
have altered the behaviour in the control group, reducing the intervention effect.  
In Van Erkelen’s NRSI, there was no control of the confounders such as age and 
sociodemographic factors. Finally, 35% (101/287) of patients at baseline were lost to 
follow up (2017). 
Excluded studies: patients with a personal history of cancer 
Two studies were excluded for having participants with a personal history of cancer but 
met other eligibility criteria: one cluster RCT and one before after study (supplementary 
material 4) (Wilson et al. 2005; Wilson et al. 2006; Orlando et al. 2011; Orlando et al. 
2013; Wu et al. 2013; Orlando et al. 2014; Orlando et al. 2016). Overall, there were four 
(22/588) to eight percent (23/282) of participants with personal history of cancer. 
Similar to the main review, the secondary outcomes reported were: appropriateness of 
referrals and uptake of preventive strategies. However, the findings were different from 
the main review: intervention had no impact on the appropriateness of genetic referrals 
(Wilson et al. 2005; Wilson et al. 2006),  but there was improved preventive uptake of 
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surveillance (breast magnetic resonance imaging) and gynaecology assessment for 
ovarian cancer screening (supplementary material 3) (Orlando et al. 2016). 
DISCUSSION 
Main findings 
This is a comprehensive systematic review on the long-term clinical impact of primary 
care assessment and management of patients with familial breast, ovarian, prostate and 
colorectal cancer risk. Our review spanned the past 37 years and identified three studies. 
None of these studies assessed the review’s primary outcome: cancer incidence, 
morbidity, mortality, survival or identification of cancer predisposition. The follow up 
period (two weeks to 12 months) would have been too short to identify the primary 
outcomes. For instance, a large community cohort study estimated that a period of five 
years is required for 1000 colorectal cancer cases to be identified from a sample size of 
500 000 recruits (UK Biobank 2007).  
The secondary outcomes predominantly evaluated short term outcomes of process and 
psychological measures; these evidence were of limited quality due to weakness in the 
study design. The strongest evidence emerged from a cluster RCT, demonstrating 
improved appropriateness of general practitioners’ genetic referral letters for patients at 
familial breast cancer risk. However, this still had a low GRADE level of certainty 
(Emery et al. 2007). 
Comparison with previous systematic review 
To our knowledge, no systematic review has evaluated the clinical impact of familial 
cancer risk assessment and management by non-specialist primary care providers in 
primary care settings. The previous four reviews covered broader areas of multifactorial 
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cancer risk assessment tools, the validity and nature of cancer family history tools and 
familial breast cancer risk assessment by genetic services (Cleophat et al. 2018; Hilgart 
et al. 2012; Qureshi et al. 2009; Walker et al. 2015). All of these reviews shared some 
similar findings to the current review.  
Walker et al. reviewed RCTs that evaluated the impact of cancer risk assessment tools 
in primary care. They identified 11 trials compared to three trials in our review, as we 
focused on familial cancer risk assessment, limited the types of cancer to those known 
to have a genetic component, grouped papers from the same study as a single trial and 
included only outcomes measured with validated tools. Despite focusing on familial 
cancer, our review findings were consistent with Walker et al.’s, specifically, there is 
limited evidence available on the effectiveness of cancer risk assessment on the uptake 
of screening and risk assessment does not increase psychological distress (2015). 
Two reviews identified between 18 to 29 cancer family history tools used in primary 
care; a third of the tools provided risk stratification and action plan for patients or 
clinicians (Cleophat et al. 2018; Qureshi et al. 2009). Compared with structured genetic 
interviews, Qureshi et al. found that the tools demonstrated a 75-100% agreement of 
risk stratification (2009). In Cleophat et al.’s review, the validation methods and results 
were inconsistent. There was no formal evaluation of clinical utility but similar to our 
review, Cleophat et al. suggested potential benefits: improved quality of genetic 
referrals, increased compliance with cancer screening, and no increase in psychological 
distress (2018).  
Finally, both our review and Hilgart et al.’s Cochrane review suggested that familial 
cancer risk assessment may improve accuracy of patients’ risk perception and anxiety, 
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even though the Cochrane review only included familial breast cancer services 
delivered by genetic specialists (2012).  
Strength of the review & included studies 
The strength of this systematic review is the robust search strategy and focused 
eligibility criteria. Restricting the evidence to the highest level of experimental study 
design but recognising the paucity of literature in this field, we expanded the inclusion 
criteria beyond RCT to NRSI. Two independent reviewers conducted the eligibility 
screen, data extraction and risk of bias assessment. To help interpret the results, we 
conducted rigorous assessment of the evidence quality using established methods from 
Cochrane and GRADE (Higgins et al. 2011a; Schünemann et al. 2013; Sterne et al. 
2016). 
Two of three included studies employed cluster RCT design, which is suitable for 
studies in primary care where cross contamination of participants in the same primary 
care practice can dilute the effect of the intervention (Emery et al. 2007; Family 
Healthware Trial). Included studies also used validated measures for psychological 
outcomes: in Van Erkelen’s study, the impact of familial cancer risk assessment on 
patient psychological outcomes were measured using STAI and HADS (2017). 
Weakness of the review & included studies 
Due to the low number of included studies with variable study designs and 
interventions, a quantitative synthesis was not feasible. The study design requirement of 
an intervention study and a comparator group increased the review’s robustness but 
limited the number of included studies. Further, risk of bias was high across all studies, 
hence the results need to be interpreted with caution. 
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Studies that combined data for patients with and without previous cancer history were 
excluded. As the aim of the review was to identify the impact of intervention on cancer 
mortality and morbidity, it was decided that participants with cancer history would not 
be included. Similarly, studies that combined outcome data for different cancers that 
could not be disentangled were excluded.  
It was difficult to have a true comparator that reflected current usual care. In Emery et 
al.’s RCT, the lead clinician in both the intervention and control arm received an 
education session on cancer genetics, although continuing medical education could be 
considered as part of usual practice (2007). In the Family Healthware trial, the control 
arm had a lengthy baseline survey, which may have had an intervention effect 
(Rubinstein et al. 2011a). Finally, studies predominantly included white educated 
females, limiting the findings’ generalisability to the wider population. 
Implication for future research 
More studies are needed in primary care settings where the majority of health 
consultations take place (NHS England 2013). Current studies are not generalizable to 
the wider population; in particular, future studies need better representation from 
deprived and ethnic minority groups. Future studies should also incorporate robust 
comparator groups and use validated outcome measures. Current studies often do not 
state the participants’ age range or personal history of cancer in the eligibility criteria, 
necessitating correspondence with the author. We suggest future studies should also 
make these inclusion criteria clearer.  
Clinical trials with longer follow up will allow for evaluation of clinical impact such as 
cancer related outcome, but with relatively low prevalence of cancers with inherited 
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predisposition, this would require studies with large sample sizes. Although classified as 
lower level of evidence, prospective cohort studies with robust design and longer follow 
up may provide good quality clinical outcome data. 
It has been 30 years since the introduction of familial cancer clinics, and since then 
there has been great advances in preventive management of familial cancer risk. We still 
need large well design studies to help us determine if systematic familial cancer risk 
assessment should be introduced as a routine case-finding approach in primary care.  
Supplementary materials 
Supplementary materials are available on the journal’s website.  
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Figure 1. PRISMA flow diagram of study selection. 
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Table 1: Summary description of included studies 
BC: breast cancer, FBC: familial breast cancer, GP: general practitioner, HADS: Hospital Anxiety Depression Scale, NRSI: non-randomised study of intervention, RCT: randomised controlled trial, STAI: State-Trait 
Anxiety Inventory 
Author, year Study 
design  
Country, setting Participants  Intervention  Comparator  Outcomes  
Emery et al. 2007 Cluster RCT 
 
 
UK, primary care 
 
Patients expressing concern about 
cancer family history 
Lead clinician attended educational 
session and given access to software 
that conducts familial risk 
assessment to inform genetic 
referrals. 
Lead clinician attended 
educational session and mailed 
familial cancer guidelines. 
  
1. Proportion of GP referrals 
consistent with guidelines 
 
2. Proportion of GP referrals 
assessed to be at increased risk by 
genetic clinic              
Family Healthware 
Trial  
 
1. O’Neill et al. 2009 
2. Acheson et al. 2010 
3. Rubinstein et al. 2011a 
4. Rubinstein et al. 2011b 
5. Ruffin et al. 2011 
6. Wang et al. 2012 
7. Wang et al. 2015 
Cluster RCT 
 
 
USA, primary care Existing patient list or patients with 
upcoming appointments 
 
 
Patient received personalised 
familial risk assessment and 
prevention messages generated by a 
software. 
 
Patient received standard 
prevention messages about 
screening and healthy lifestyle 
choices. 
 
1. Adherence to cancer screening 
 
2. Cognitive: Patient risk perception 
Van Erkelens et al. 
2017 
NRSI: 
uncontrolled 
before after 
study 
The Netherlands, 
population BC 
screening 
programme 
Women attending population BC 
screening 
 
 
Patient completed FBC risk 
assessment and received risk status 
and advice online. 
Same patients two weeks after 
initial FBC risk assessment. 
Psychological: Patient anxiety & 
depression (STAI & HADS) 
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Table 2: GRADE evidence profile 
Outcome / 
cancer 
Effect* Number of 
participants 
(studies) 
GRADE 
criteria 
    Certainty in 
evidence 
Risk of bias Inconsistency Indirectness Imprecision Publication bias 
I. Appropriateness of specialist referral: general practitioners’ referral letter (Emery et al. 2007) 
 
Breast Proportions meeting referral guidelines 
 
OR 4.5 (1.6 to 13.1) 
 
45 practices,  
167 patients  
(1 cluster RCT) 
Present Not applicable Not serious Absent 
 
 
Not applicable      a 
Low  
Proportions confirmed at increased risk 
at genetic clinic 
 
OR 1.4 (0.6 to 3.5) 
 
45 practices,  
111 patients  
(1 cluster RCT) 
Present Not applicable Not serious Present Not applicable         b 
Very low  
Colorectal Proportions meeting referral guidelines 
 
OR 6.5 (0.5 to 83.7) 
 
45 practices,  
101 patients  
(1 cluster RCT) 
Present Not applicable Not serious Present Not applicable         c 
Very low 
Proportions confirmed at increased risk 
at genetic clinic 
 
OR 0.2 (0.1 to 0.8) 
 
45 practices,  
74 patients  
(1 cluster RCT) 
Present Not applicable Not serious Absent Not applicable         d 
Very low 
* Effects are adjusted odds ratio (95% confidence intervals) unless otherwise specified 
a downgraded by 1 for high risk of bias (allocation concealment, blinding, responder bias), downgraded by 1 as unable to assess inconsistency and publication bias 
b downgraded by 2 for high risk of bias (allocation concealment, blinding, incomplete outcome (participant non-attendance), responder bias) and imprecision (confidence interval 
crossing one), downgraded by 1 as unable to assess inconsistency and publication bias 
c downgraded by 2 for high risk of bias (allocation concealment, blinding, responder bias) and imprecision (wide confidence interval), downgraded by 1 as unable to assess 
inconsistency and publication bias 
d downgraded by 2 for high risk of bias (allocation concealment, blinding, incomplete outcome (participant non-attendance), responder bias), downgraded by 1 as unable to assess 
inconsistency and publication bias 
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Outcome / 
cancer 
Effect* Number of 
participants 
(studies) 
GRADE criteria Certainty in 
evidence Risk of bias Inconsistency Indirectness Imprecision Publication bias 
II. Uptake of preventive strategies: improvement in proportion of patients adherent to risk based screening (Rubinstein et al. 2011a) 
 
Breast Mammography 
 
9% (intervention) vs 7% (control) 
improvement, p=0.82 
 
41 practices, 
2063 patients 
(1 cluster RCT) 
Present Not applicable Absent Present Not applicable         a 
Very low 
Colorectal Colon cancer screening 
 
8% vs 7% improvement, p=0.95 
 
41 practices, 
2016 patients 
(1 cluster RCT) 
Present Not applicable Absent Present Not applicable         b 
Very low 
 
* Effects are difference in screening adherence pre- and post-intervention period, p value for comparison between study arms, adjusting for practice clustering, risk, and baseline 
adherence. 
a, b,  Downgraded by 2 for high risk of bias (randomisation, allocation concealment, blinding, incomplete outcome, selective reporting) and imprecision (no sample size and 
confidence interval crosses zero); downgraded by 1 as unable to assess inconsistency and publication bias 
 
 
Outcome / 
cancer 
Effect* Number of 
participants 
(studies) 
GRADE criteria Certainty in 
evidence Risk of bias Inconsistency Indirectness Imprecision Publication bias 
III.  Psychological: patients’ anxiety & distress (Van Erkelens et al. 2017) 
 
Breast  State anxiety (STAI) immediately after self-
test  
 
Increased risk    -2 (-6 to 2) 
Population risk  -2 (-2 to -1) 
 
186 patients  
(1 uncontrolled 
before after study) 
Present Not applicable Absent Present Not applicable         a 
Very low 
Breast  State anxiety (STAI) two weeks after self-
test 
 
Increased risk     3 (-5 to 10) 
Population risk  -3 (-5 to -2) 
 
186 patients  
(1 uncontrolled 
before after study) 
Present Not applicable Absent Present Not applicable         b 
Very low 
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Breast  Trait anxiety (STAI) two weeks after self-
test 
 
Increased risk      0 (-3 to 4) 
Population risk  -1 (-2 to -1) 
 
186 patients  
(1 uncontrolled 
before after study) 
Present Not applicable Absent Present Not applicable         c 
Very low 
Breast  Hospital anxiety & depression score 
(HADS) two weeks after self-test 
 
Increased risk     1 (-3 to 6) 
Population risk  -0 (-1 to 0) 
186 patients  
(1 uncontrolled 
before after study) 
Present Not applicable Absent Present Not applicable         d 
Very low 
*Effects are mean change from baseline (95% confidence intervals) unless otherwise specified 
 
a, b, c, d Downgraded by 2 for critical risk of bias (non-randomised studies of intervention, confounding, missing data) and imprecision (no sample size calculation) , downgraded by 
1 as unable to assess inconsistency and publication bias 
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Table 3: Risk of bias table  
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Emery et al. 2007 + - - + - + ? - 
Family Healthware Trial ? ? - - - ? - - 
    +  low risk    ?  unclear risk   -  high risk 
31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
NRSI 
(ROBINS-I 
risk of bias 
tool) 
C
o
n
fo
u
n
d
in
g
 
P
a
rt
ic
ip
a
n
ts
 s
el
ec
ti
o
n
 
C
la
ss
if
ic
a
ti
o
n
 o
f 
in
te
rv
en
ti
o
n
 
D
ev
ia
ti
o
n
 f
ro
m
 i
n
te
n
d
ed
 i
n
te
rv
en
ti
o
n
s 
M
is
si
n
g
 d
a
ta
  
M
ea
su
re
m
en
t 
o
f 
o
u
tc
o
m
es
 
S
el
ec
ti
o
n
 o
f 
re
p
o
rt
ed
 r
e
su
lt
 
O
v
er
a
ll
 b
ia
s 
Van Erkelens et al. 
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Supplementary material 1: Search strategy 
MEDLINE 
1 exp Prostatic Neoplasms/ 
2 exp Breast Neoplasms/ 
3 exp Ovarian Neoplasms/ 
4 exp Colorectal Neoplasms/ 
5 ((prostat* or breast* or mammar* or ovar* or colon* or colorect*) adj3 (cancer* or neoplasm* or carcinoma* or tumo?r* or 
malignan* or adenocarcinoma* or sarcoma*)).mp. 
6 Or/1-5 
7 exp Genetic Predisposition to Disease/ 
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8 exp Neoplastic Syndromes, Hereditary/ 
9 (famil* or heredit* or inherit* or gene* or predispos* or susceptib*).mp. 
10 exp Genes, BRCA2/ or Genes, BRCA1/ 
11 exp Tumor Suppressor Protein p53/ 
12 exp Genetics 
13 Or/7-12 
14 Exp primary health care/ or exp general practice/ or exp family practice/ or exp physicians, family/ or exp community health 
services/ or exp ambulatory care/ or exp ambulatory care facilities/ or exp general practitioners/ or exp physicians, primary care/ 
15 (Primary adj2 care).mp. 
16 General practi*.mp. 
17 (Family adj2 (practi* or medicine or care or physic*)).mp. 
18 communit*.mp. 
19 Or/14-18 
20 And/6, 13, 19 
21 limit 20 to (english language and yr="1980 -Current" and humans) 
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EMBASE 
1 exp prostate tumor/ or exp prostate cancer/ 
2 exp breast tumor/ or exp breast cancer/ 
3 exp ovary tumor/ or exp ovary cancer/ 
4 exp colon cancer/ or exp colon tumor/ or exp rectum tumor/ or exp rectum cancer/ or colorectal tumor/ or colorectal cancer/ 
5 ((prostat* or breast* or mammar* or ovar* or colon* or colorect*) adj3 (cancer* or neoplasm* or carcinoma* or tumo?r* or 
malignan* or adenocarcinoma* or sarcoma*)).mp. 
6 or/1-5 
7 exp genetic predisposition/ 
8 exp hereditary tumor/ or exp cancer genetics/ or exp familial disease/ or exp tumor syndrome/ or exp familial colon polyposis/ or 
exp "hereditary breast and ovarian cancer syndrome"/ or exp hereditary colorectal cancer/ or exp heredity/ 
9 exp genetics/ 
10 (famil* or heredit* or inherit* or gene* or predispos* or susceptib*).mp. 
11 exp oncogene/ 
12 exp primary medical care/ or exp primary health care/ 
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13 exp general practice/ or exp general practitioner/ 
14 exp family medicine/ 
15 exp community care/ 
16 exp ambulatory care/ 
17 (Primary adj2 care).mp. 
18 General practi*.mp. 
19 (Family adj2 (practi* or medicine or care or physic*)).mp. 
20 communit*.mp. 
21 or/7-11 
22 or/12-20 
23 6 and 21 and 22 
24 limit 23 to (human and english language and yr="1980 -Current") 
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CINAHL  
1 (MH "Prostatic Neoplasms+") OR (MH "Breast Neoplasms+") OR (MH "Ovarian Neoplasms+") OR (MH "Colorectal 
Neoplasms+") OR ""(prostat* or breast* or mammar* or ovar* or colon* or colorect*) N3 (cancer* or neoplasm* or carcinoma* 
or tumo#r* or malignan* or adenocarcinoma* or sarcoma*)""  
2 (MH "Neoplastic Syndromes, Hereditary+") OR ""famil* or heredit* or inherit* or gene* or predispos* or susceptib*"" OR 
(MH "Genes, BRCA") OR (MH "Genetics, Medical+")   
3 (MH "Primary Health Care") OR (MH "Physicians, Family") OR (MH "Family Practice") OR (MH "Ambulatory Care") OR 
(MH "Community Health Centers+") OR (MH "Ambulatory Care Facilities+") OR ""primary N2 care"" OR ""General practi*"" 
OR "“(Family N2 (practi* or medicine or care or physic*)”"  OR "communit*" 
 Limiters - Published Date: 19800101-20171231 
Narrow by Language: - english 
Search modes - Boolean/Phrase 
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Cochrane CENTRAL  
#1 MeSH descriptor: [Prostatic Neoplasms] explode all trees 
#2 MeSH descriptor: [Breast Neoplasms] explode all trees 
#3 MeSH descriptor: [Ovarian Neoplasms] explode all trees 
#4 MeSH descriptor: [Colorectal Neoplasms] explode all trees 
#5 (prostat* or breast* or mammar* or ovar* or colon* or colorect*) near/3 (cancer* or neoplasm* or carcinoma* or tumo*r* or 
malignan* or adenocarcinoma* or sarcoma*) 
#6 #1 or #2 or #3 or #4 or #5 
#7 MeSH descriptor: [Genetic Predisposition to Disease] explode all trees 
#8 MeSH descriptor: [Neoplastic Syndromes, Hereditary] explode all trees 
#9 MeSH descriptor: [Genes, BRCA1] explode all trees 
#10 MeSH descriptor: [Genes, BRCA2] explode all trees 
#11 MeSH descriptor: [Genes, p53] explode all trees 
#12 MeSH descriptor: [Genetics] explode all trees 
#13 famil* or heredit* or inherit* or gene* or predispos* or susceptib* 
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#14 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 
#15 MeSH descriptor: [Primary Health Care] explode all trees 
#16 MeSH descriptor: [Physicians, Primary Care] explode all trees 
#17 MeSH descriptor: [General Practice] explode all trees 
#18 MeSH descriptor: [General Practitioners] explode all trees 
#19 MeSH descriptor: [Physicians, Family] explode all trees 
#20 MeSH descriptor: [Ambulatory Care] explode all trees 
#21 MeSH descriptor: [Ambulatory Care Facilities] explode all trees 
#22 MeSH descriptor: [Community Health Services] explode all trees 
#23 "Primary near/2 care" 
#24 "General practi*" 
#25 Family near/2 (practi* or medicine or care or physic*) 
#26 communit* 
#27 #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 
#28 #6 AND #14 AND #27 
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U.S. National Institutes of Health (www.clinicaltrials.gov)   
 
Familial Breast Cancer OR hereditary breast cancer OR familial ovarian cancer OR hereditary ovarian cancer OR familial prostate cancer 
OR hereditary prostate cancer OR familial colorectal cancer OR hereditary colorectal cancer 
 
 
ISRCTN registry (www.isrctn.com)    
Familial breast cancer 
Hereditary breast cancer 
Familial ovarian cancer 
Hereditary ovarian cancer 
Familial prostate cancer 
Hereditary prostate cancer 
Familial colorectal cancer 
Hereditary colorectal cancer 
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WHO International Clinical Trials Registry Platform (ICTRP)    (www.who.int/ictrp/en)    
(prostate cancer OR breast cancer OR ovarian cancer OR colorectal cancer) AND (familial OR hereditary OR inherited OR genetic) 
 
 
The Networked Digital Library of Theses and Dissertations 
"("prostate cancer" OR "breast cancer" OR "ovarian cancer" OR "colorectal cancer") AND ("familial" OR "hereditary" OR "genetic" OR 
"inherited") AND ("primary care" OR "general practice" OR "general practitioners" OR "family practice" OR "family physicians" OR 
"community health" OR "ambulatory care")" 
Year 1980 -2017, English  
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Supplementary material 2: List of excluded studies 
No Study reference Reason for exclusion 
1.  Anonymous. UK MoD to conduct cancer screening trial. Manufacturing Chemist. 
2001;72(11):9 
I1: Not a study on strategies to 
identify and manage patients with 
familial cancer risk. 
2.  Appel SJ, Cleiment RJ. Identifying Women at Risk for Hereditary Breast and Ovarian Cancer 
Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers. 
Journal of National Black Nurses Association. 2015;26(2):17-26. 
I3: Specialist nurse navigator. 
3.  Baer HJ, Schneider LI, Colditz GA, et al. Evaluation of a web-based risk assessment tool in 
the primary care setting. Journal of General Internal Medicine. 2012;27:S187. 
Duplicate. 
4.  Baer HJ, Schneider LI, Colditz GA, et al. Use of a web-based risk appraisal tool for assessing 
family history and lifestyle factors in primary care. Journal of General Internal Medicine. 
2013;28(6):817-824. 
P: Participants had previous cancer; 
study outcome not included 
(increased family history 
documentation). 
5.  Bale PW, Pearce K. The role of primary care physicians in the prevention and management of 
colorectal cancer. J Ky Med Assoc. 2009;107(3):88-92 
D: Review article. 
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6.  Beck S, Breckenridge-Potterf S, Wallace S, Ware J, Asay E, Giles RT. The family High-Risk 
Program: targeted cancer prevention. Oncology Nursing Forum. 1988;15(3):301-306. 
I3: Family history questionnaire 
analysed by the university team, not 
primary care.  
7.  Bellcross CA, Lemke AA, Pape LS, Tess AL, Meisner LT. Evaluation of a breast/ovarian 
cancer genetics referral screening tool in a mammography population. Genet Med. 
2009;11(11):783-789. 
 
D: Accuracy study. 
8.  Bellcross C. Identification and Referral of Women at Risk for Hereditary Breast/Ovarian 
Cancer. 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT02786147. Accessed 
September 24, 2018. 
I1: Preselected high-risk 
participants. Study aim is to identify 
the most effective means of follow 
up for women who screened positive 
on Breast Cancer Genetics Referral 
Screening Tool. Ongoing trial. 
9.  Birt L, Emery JD, Prevost AT, Sutton S, Walter FM. Psychological impact of family history 
risk assessment in primary care: a mixed methods study. Fam Pract. 2014;31(4):409-418. 
I2: Combined data for different 
cancer types. 
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10.  Biswas S, Atienza P, Chipman J, et al. A two-stage approach to genetic risk assessment in 
primary care. Breast Cancer Res Treat. 2016;155(2):375-383. 
D: Accuracy study. 
11.  Bondurant KL, Harvey S, Klimberg S, Kadlubar S, Phillips MM. Establishment of a southern 
breast cancer cohort. Breast J. 2011;17(3):281-288. 
I1: Not an interventional study on 
familial risk identification and 
management. 
12.  Bowen DJ, Powers D. Effects of a mail and telephone intervention on breast health behaviors. 
Health Education & Behavior. 2010;37(4):479-489. 
I3: No PCP involvement, results not 
to be given to health provider to 
avoid risk of insurance 
discrimination. 
13.  Bowman MA, Neale AV, Seehusen DA. Research on clinical decisions made daily in family 
medicine. Journal of the American Board of Family Medicine. 2017;30(3):269-271 
I1: Not a study on strategies to 
identify and manage patients with 
familial cancer risk. Editor’s note. 
14.  Brindley C. Proactive familial breast cancer risk assessment in primary care (Phase 2) 2014. 
Available at: http://www.isrctn.com/ISRCTN16117197. Accessed September 24, 2018. 
D: Pending publication. 
44 
 
15.  Brinton JT, Barke LD, Freivogel ME, Jackson S, O'Donnell CI, Glueck DH. Breast Cancer 
Risk Assessment in 64,659 Women at a Single High-Volume Mammography Clinic. 
Academic Radiology. 2012;19(1):95-99. 
P: Included patient with DCIS and 
LCIS. 
16.  Bruner DW, Baffoe-Bonnie A, Miller S, et al. Prostate cancer risk assessment program. A 
model for the early detection of prostate cancer. Oncology (Williston Park). 1999;13(3):325-
334; discussion 337-329, 343-324 pas. 
I3: Specialist provider. 
17.  Burke C, Leach B, Dai J, et al. Community uptake of an online CRC risk assessment. 
American Journal of Gastroenterology. 2010;105:S549. 
Duplicate. 
18.  Burke CA, Leach B, Dai J, et al. The community uptake of an online CRC risk assessment and 
its utility to assess for a potential hereditary colon cancer syndrome. Hereditary Cancer in 
Clinical Practice. 2011;9:5-6. 
I3: Assessment self-administered by 
patients, unclear who acted on 
results. Multispecialty academic 
medical centre. Patients with 
previous cancer. No reply from 
author.  
19.  Byers T, Lynch HT, Thun M. Biomarkers of cancer risk: at a turning point? Patient Care for 
the Nurse Practitioner. 2002;5(8):9p-9p. 
D: Review article. 
45 
 
20.  Campacci N, Ramadan L, Caron TB, et al. Identification of at-risk families for hereditary 
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Supplementary material 3: Outcome table 
Outcomes Study ID Results 
Appropriateness of specialist referrals 
Included studies Emery et al. 
2007 
Proportions of GP referral letters meeting guidelines 
                
 
Proportions of GP referrals confirmed at increased risk at genetic clinic 
NB: Odds ratio for intervention vs. control allowing for cluster randomised design. 
 
 Intervention Control OR (95% CI) 
Breast 93% (99/107) 73% (44/60) 4.5 (1.6 to 13.1) 
Bowel 99% (15/76) 92% (23/25) 6.5 (0.5 to 83.7) 
Combined  95% (174/183) 79% (67/85) 5.2 (1.7 to 15.8) 
   P=0.006 
 Intervention Control OR (95% CI) 
Breast 77% (60/78) 70% (23/33) 1.4 (0.6 to 3.5) 
Bowel 56% (30/54) 85% (17/20) 0.2 (0.1 to 0.8) 
Combined  68% (90/132) 75% (40/53) 0.7 (0.3 to 1.5) 
   P=0.35 
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Studies excluded for 
having participants with 
personal history of 
cancer 
Wilson et al. 
2005; Wilson et 
al. 2006 
Proportion of GP referral letters categorised as increased risk  
 
 
 
 
Proportion of referred patients confirmed at increased risk at genetic clinic 
 
 
a Pearson x2 
b  Pearson x2 adjusted for clustering within practices 
 
 
 Intervention Control RR (95% CI) P valuea 
Pre 
intervention 
55% (53/96) 65% (24/37) 0.85 (0.63 to 1.15) 0.31 
(0.31)b 
Post 
intervention 
65% (66/102) 60% (22/37) 1.09 (0.80 to 1.47) 0.57 
 Intervention Control RR (95% CI) P valueb 
Pre 
intervention 
46% (40/88) 65% (22/34) 0.70 (0.50 to 0.99) 0.06 
Post 
intervention 
58% (49/85) 48% (14/29) 1.18 (0.88 to 1.37) 0.38 
65 
 
Uptake of preventive strategies 
Included studies Family 
healthware trial 
 
Proportion of patients adherent to cancer screening (Rubinstein et al. 2011a) 
Reported in text only: 
 Intervention (%) Control (%) P valuea 
 Baseline 6 months Baseline 6 months  
Mammography 73 82 78 85 0.82 
Colorectal 
cancer screening 
76 84 77 84 0.95 
acomparison between arms, adjusted for clustering, risk, baseline adherence 
 
Proportion of non-adherent patients becoming adherent to cancer screening at six months 
(Rubinstein et al. 2011a) 
 Intervention 
%improved 
Control 
%improved 
OR (95% CI)a P value 
Breast cancer risk    
Strong 60% (27/45) 65% (17/26) 0.8 (0.3 to 2.2) 0.65 
Moderate 63% (22/35) 59% (10/17) 0.7 (0.4 to 1.4) 0.28 
Weak 58% (157/272) 64% (77/120) 1.0 (0.6 to 1.6) 0.92 
Overallb 59% (206/352) 64% (104/163) 0.9 (0.6 to 1.5) 0.82 
Colorectal cancer risk    
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Strong 36% (5/14) 21% (3/14) 1.9 (0.5 to 7.2) 0.33 
Moderate 16% (9/55) 18% (6/33) 0.9 (0.3 to 3.1) 0.86 
Weak 40% (90/222) 43% (58/134) 0.9 (0.6 to 1.6) 0.77 
Overallb 36% (104/291) 37% (67/181) 0.9 (0.6 to 1.4) 0.77 
Breast cancer – mammography 
Colon cancer – faecal occult blood, sigmoidoscopy, or colonoscopy 
aUnadjusted OR 
bAdjusted for risk 
 
 
Proportion of women with ovaries having CA-125 blood test and transvaginal ultrasound 
during the six month follow up (Rubinstein et al. 2011a) 
Reported in text only: CA-125 test 47 (2%), transvaginal ultrasound 100 (5%), no measurable 
difference between the study arms (p>0.09) (separate data for study arms or risk level not 
provided) 
Studies excluded for 
having participants with 
personal history of 
cancer 
MeTree Proportions of patients receiving risk-management strategy before and after using MeTree 
(Orlando et al. 2016) 
 Increased risk (received 
appropriate 
management) 
Not at increased risk 
(received management 
inappropriately) 
Risk-management strategy  Before 
MeTree 
After 
MeTree 
Before 
MeTree 
After 
MeTree 
Breast cancer: Magnetic 
Resonance Imaging (MRI) 
25% (1/4) 75% (3/4) 2% (5/280) 0.4% (1/280) 
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Breast cancer: 
chemoprevention 
0% (0/26) 0% (0/26) 0% (0/258) 0% (0/258) 
Ovarian cancer: referral to 
gynaecology 
0% (0/2) 50% (1/2) 4% (12/282) 3% (9/282) 
NB: Women only. Colon cancer risk recommendations were excluded from this table because the assessment could 
only be accurately completed in those < 50 years of age. 
 
 
 
Control arm’s breast cancer screening rates suggest temporal changes did not result in increased 
breast cancer screening in the intervention arm (Orlando et al. 2016) 
Reported in text only: 
Control screening rate Before After P value 
Breast MRI 0% 1.8% 0.32 
Mammography 62.5% 48.2% 0.13 
 
 
Screening rates after study 
date 
Intervention Control P value 
Breast MRI 0.74% 1.8% 0.371 
Mammography 76.0% 48.2% 0.003 
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Cognitive effect: Patients’ risk perception 
Included studies Family 
healthware trial 
Proportion of patient with risk perception consistent with risk status by Family Healthware at 
baseline (Wang et al. 2012) 
 
 Low familial risk High familial risk  
Breast cancer   
Intervention 92% (1152/1250) 52% (212/405) 
Control 92% (602/655) 49% (96/194) 
Ovarian cancer   
Intervention 96% (1324/1382) 30% (42/140) 
Control 97% (685/707) 27% (20/73) 
Colon cancer   
Intervention 94% (1893/2015) 46% (146 /315) 
Control 95% (1015/1069)  42% (78/186) 
 
 
Proportion of under-estimator shifting to high perceived risk (consistent with risk status) and 
logistic regression model predicting this shift at six months follow up (Wang et al. 2012) 
Cancer N Intervention Control OR (95% CI)a 
Breast 276 18% 14% 1.48 (0.61 to 3.58) 
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Ovarian 140 8% 13% 0.52 (0.10 to 2.59) 
Colon 258 17% 10% 1.89 (0.99 to 3.59)b 
a Control arm as reference, models adjusted for practice clustering and potential site difference 
b Statistically significant (p=0.05) 
Psychological effect: Patients’ anxiety & depression 
Included studies Van Erkelens et 
al. 2017 
Anxiety & depression at baseline, immediately after and two weeks after familial breast cancer 
risk self-assessment 
Outcome N Baseline 
mean (SD) 
After mean 
(SD) 
Mean change from 
baseline (95% CI) 
P value 
Immediately after     
State anxiety (STAI 20-80)a 
Increased risk 15 36 (12) 34 (13) -2 (-6 to 2) 0.357 
Population risk 272 33 (10) 31 (10) -2 (-2 to -1) <0.001 
Two weeks after     
State anxiety (STAI 20-80)a 
Increased risk 11 33 (10) 35 (11) 3 (-5 to 10) 0.453 
Population risk 175 33 (10) 30 (10) -3 (-5 to -2) <0.001 
Trait anxiety (STAI 20-80)a 
Increased risk 11 35 (11) 35 (12) 0 (-3 to 4) 0.800 
Population risk 175 34 (9) 32 (9) -1 (-2 to -1) 0.002 
Depression (HADS 0-22)b 
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Increased risk 11 8 (8) 9 (9) 1 (-3 to 6) 0.481 
Population risk 175 7 (5) 7 (6) -0 (-1 to 0) 0.438 
a general population mean (SD) 39 (11-13), higher scores refer to more anxiety 
b clinical significance =>12, higher scores refer to more depression 
aOR: adjusted odds ratio, CI: confidence intervals, GP: general practitioner, HADS: hospital anxiety and depression score, OR: odds ratio, RR: relative risk, SD: standard 
deviation, STAI: state trait anxiety inventory 
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Supplemental material 4: Summary description of studies excluded for having participants with personal history of cancer 
 
BC: breast cancer, GP: general practitioner, RCT: randomised controlled trial  * Correspondence with study author 
 
Author, year Study design  Setting Personal history of cancer Participants  Intervention Comparator Outcomes  
1. Wilson et al. 
2005 
2. Wilson et al. 
2006  
Cluster RCT UK, 
general 
practice  
 
Pre-intervention* 
Breast: 3/185 (2%),  
Other cancer: 10/185 (5%) 
 
Post-intervention* 
Breast: 6/97 (6%),  
Other cancer: 4/97 (4%) 
Women referred for BC 
genetic counselling 
Intervention package for 
GP:  
1. educational session & 
materials 
2. software (referral 
guide) 
3. email-based link with 
the cancer genetic clinic 
Scottish referral 
guidelines mailed 
to all GPs by the 
Department of 
Health. 
1. Proportion of GP 
referral letters 
categorised as 
increased risk 
 
2. Proportion of 
referred patients 
confirmed at 
increased risk by 
genetic clinic 
 
MeTree  
 
1. Orlando et al. 
2011 
2. Orlando et al. 
2013 
3. Wu et al. 2013 
4. Orlando et al. 
2014 
5. Orlando et al. 
2016 
Controlled 
hybrid type two 
implementation-
effectiveness 
clinical trial 
(controlled 
before & after 
study) 
USA, 
primary 
care clinics 
 
 
 
Colon 3/588 (0.5%), Breast 
14/588 (2%), 
Ovarian 1/588 (0.2%), 
Hereditary cancer 4/588 
(0.7%) 
Patients with upcoming 
well visit 
Software to collect 
personal and family 
history from patient, 
stratify risk, generate 
decision support reports 
for patient and provider. 
 
 
Same patients had 
medical records 
reviewed at 12 
months. 
 
Agreement between 
risk level and 
evidence-based risk 
management 
(uptake of 
preventive strategy) 
 
